Andrew Hider
Analyst · TD Cowen
Thank you, David. Good morning, ladies and gentlemen, and thank you for joining us. This has been an exciting and transformational few months for ATS, during which we successfully completed our U.S. IPO and New York Stock Exchange listing. This represents an important milestone and supports our strategic growth objectives while providing increased liquidity in our shares and additional flexibility for M&A. Today, we reported a strong start to fiscal '24, including record revenues, supported by solid bookings, backlog and adjusted earnings. These results reflect our team's disciplined execution of the ATS business model. Our ABM has reached a level of maturity that allows us to refine our approach and add new tools to drive performance for our customers and shareholders. First, I will update you on the business and Ryan will provide his financial report. Starting with our financial value drivers. Order bookings for the quarter were $690 million and included growth in Life Sciences and continued strength in EV and Food and Beverage. Q1 revenues were a record $754 million, up 23% from Q1 last year, including strong organic growth. Adjusted earnings from operations in Q1 were $102 million, up 29% versus Q1 last year. Moving to our outlook. We ended the quarter with order backlog of over $2 billion. This was anchored by our strong bookings in Life Sciences, partially offset by the expected revenue ramp up on our EV projects and execution of primary processing projects ahead of the harvest season in Food and Beverage. As a reminder, the timing of customer decisions on larger opportunities can cause variability in order bookings from quarter-to-quarter. By market, life sciences backlog was $783 million. Of note, our Q1 bookings included several key wins in strategic submarkets, including contact lenses, auto injectors and diabetes care, along with pharma and radiopharma. We secured another significant order based on our Symphoni, our innovative high-speed assembly technology. Overall, the life sciences funnel for fiscal '24 remains strong. Transportation ending backlog was $834 million, up 124% year-over-year as we continue to execute on our current EV programs. Our existing programs are being executed well and are on track from a cost and timing perspective. Because of the strategic nature of EV program and large order values, this can cause variability in bookings. That said, our transportation funnel remains strong, and we remain well positioned given our significant experience and expertise in this space. In food and beverage, quarterly bookings were solid and ending backlog was $188 million, up 15% year-over-year, even as our teams delivered on projects and backlog ahead of the tomato harvest season. Our funnel remains strong. Timing of the summer harvest season drives some seasonality in this vertical. In energy, the nuclear market continues to provide long-term opportunities, including new public sector interest. The focus on clean, sustainable energy to support future subtle needs, including grid requirements for electric vehicles, is a driver for our business as is the adoption of carbon reduction targets. ATS is well positioned to support in several areas as customers add and refurbish nuclear power plants and commercialize small modular reactors. We also have specialized skills in energy storage and continue to work with customers on select opportunities. In consumer products, our backlog and funnel are stable. However, inflationary pressures continue to have an effect on discretionary spending in the personal care markets, which may impact timing of some customer investments. On digital, to create real value out of production, digitization, our customers are looking for a partner who is strong in both automation integration and domain knowledge. Our teams are helping customers understand how to capture data, and more importantly, how to extract value from that data to drive impact. For example, a major global customer utilizing our IoT platform for plant performance management recently awarded us with a global management services contract for digital services. Another life sciences customer recently launched a pilot with us for a global IoT platform for performance management. On after-sales services, we are actively engaged with customers as we leverage both technology and services to provide a better customer experience and outcome. For example, our enhanced remote support platform streamlines the process of contacting ATS support simply by scanning a QR code. With one customer, this ease of contact has led to an annual remote service contract, leveraging the technology and our subject matter experts. Also, on after-sales services, our regional networks and service centers are training and onboarding new resources to support our customers in critical geographic regions. The recent acquisition of Triad provides extended capabilities to support customers with predictive maintenance. On supply chain, material cost and lead time pressures remain and will take time to work through some of our larger projects. We have started to see some improvements in both pricing and lead times in certain areas. Countermeasures that were created to combat volatility throughout much of fiscal '23 remain in effect, allowing us to stay on schedule with our operations. Our ATS business model, our ABM playbook continues to create a competitive advantage. During the quarter, we completed 45 ABM events across all business groups and geographies. We use our ABM tools to drive improvements in all aspects of our business, not just on the shop floor. The ABM itself is also subject to continuous improvement. We constantly challenge ourselves on ABM tools and events to drive impact and stay focused on our value drivers. I'm pleased that our ABM is evolving and improving with time and use.In June, we hosted our annual ATS Leadership Conference. The theme was building the best ATS and was aligned to our 3 core values of people, process and performance. It provided an opportunity for our leaders to see examples of the ABM in action across our decentralized business as we drive value for our employees, customers and shareholders. On M&A, we recently announced and closed 2 acquisitions, Yazzoom in Q1 and Odyssey Validation Consultants in early Q2. Both are part of our Process Automation Group and enhance our capabilities in AI, process optimization and digital services. Our M&A funnel remains active and healthy. And with our recent equity offering and listing on the NYSE, we have the balance sheet and financial capacity to move quickly should a potential opportunity meet our strict acquisition criteria. On sustainability, ATS recently earned a bronze medal from EcoVadis, one of the world's leading providers of business sustainability ratings. This award speaks to our ongoing commitment to improve sustainability within ATS and leverage our solutions to help customers achieve their sustainability goals. Our teams are working closely with our global customers to meet their needs through energy-efficient automation and energy management solutions. We are actively monitoring regulatory developments, including international reporting standards and more specific regional requirements. We look forward to releasing our next sustainability report later this year. On innovation, we continue to deploy capital and leverage talent to create differentiated enabling solutions that generate attractive returns for our customers and shareholders. When customers visit our sites where innovations are displayed, their enthusiasm is clear. In particular, our patented Symphoni technology, on view in our ATS Innovation Center in Cambridge, Ontario is a good example of our investment in leading-edge technology with applications across life sciences, in addition to other possible market applications that we will explore in the future. A few other innovation highlights from the quarter. Our Comecer team launched its MIKROS machine for dispensing microfluid drops of radioisotopes used in the preparation of radiopharmaceuticals and built on its contribution to automating the production of prostate cancer therapies. Our SP team has developed its EZ-2 Bionic automated evaporator for integration into automated chemistry lines, which enables the production of pharmaceuticals that use new approaches to delivering drugs to target cells within a patient. Finally, our ATS Innovation Center developed a novel method for performing ultrasonic welding using our Symphoni platform that we believe have a variety of applications.In summary, disciplined adherence to our Build, Grow and Expand strategy is driving positive results. Our strong backlog and funnel give us confidence moving forward with a focus on operational excellence. We will continue to build the best ATS for our employees, customers and shareholders. Now, I'll turn the call over to Ryan. Ryan, over to you.